Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.
Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.
Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.
Liver Regenerative Medicine and Liver Disease
Submission Deadline: July 31, 2020 (Open) Submit Now
Natesh Parashurama, MD, PhD
Assistant Professor, Department of Chemical and Biological Engineering, School of Engineering and Applied Sciences, University at Buffalo, United States
Research Interests: Liver and pancreas stem cell biology; synthetic biology; differentiation; cell therapy; organogenesis; disease modeling; tissue engineering; multimodality molecular imaging; monitoring molecular events in living subjects
About this topic
Investigation of the liver has been a paradigm for understanding molecular regulation of organ development, organogenesis, regeneration, and fetal organ physiology. Along these lines, the liver, compared to other organs, has been ahead in establishing liver cell therapy, gene therapy, organ transplantation, bioartificial organs, adult and pluripotent stem cell biology, and stem cell reprogramming. Liver regenerative programs are an important part of normal physiology as well as the pathophysiologic response to cellular injury. Not surprisingly, regenerative programs connect directly to disease processes like fibrosis, cirrhosis, cancer, and inflammation. Recently, this has culminated in a series of exciting studies demonstrating multiple potential adult stem cell populations in the liver, regenerative capacity of adult hepatocytes, in vivo reprogramming, advances in stem cells and stem cell-derived organoid technology for disease modeling and therapy, replacement of liver and biliary tissue, and advances in liver regeneration studies. Thus, liver regenerative medicine continues to advance at an unprecedented pace. We welcome exciting manuscripts in this emerging area.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.